К содержанию
Dr. Tara EinullaevaMedical oncologist

Diagnosis and tests 7 min

Pathology slide review: when a second look changes the diagnosis

Why get a pathology review, how often it changes the diagnosis and treatment, when it matters most and how to obtain your slides and blocks for review.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026

A pathology slide review is a second assessment of your tissue by another pathologist, usually at a laboratory with wide experience in your type of tumor. In most cases it confirms the diagnosis. But in studies a noticeable share of reviews find discrepancies that change treatment — which is why, for complex and rare tumors, I consider it an essential step.

What slides and blocks are

After a biopsy or surgery the tissue is fixed and embedded in paraffin — this is the block. Thin sections are cut from the block, stained and placed on glass slides — these are the slides. The pathologist looks at the slides under a microscope and writes the report.

For a review you need:

  • the slides — to see what the first pathologist saw;
  • the blocks — to cut new sections and repeat immunohistochemistry and molecular tests;
  • a copy of the original report and information on where the tissue was taken from.

I explain how to read the report itself in the article “How to read a pathology report”.

How often a review changes the diagnosis

The numbers depend heavily on the tumor type and on who sends the material. Here is what large studies show:

Study What was reviewed Result
MD Anderson Cancer Center, 2014 2,718 cases referred to a cancer center 6.2% had a major discrepancy that could affect treatment
MD Anderson Cancer Center, 2015 1,970 breast cancer cases 11.5% had a clinically significant discrepancy
French Sarcoma Group, 2018 2,425 patients with sarcomas, GIST and desmoid tumors in 14% the diagnosis after central review differed from the original

In the breast cancer study the histological type was what changed most often, and a quarter of the significant discrepancies concerned ER, PR and HER2 receptor assessment. This directly affects the choice of hormone therapy and targeted drugs.

A review isn’t a sign of distrust in the first doctor. Some tumors are genuinely difficult to diagnose, and a second pathologist’s opinion is a standard part of how cancer centers work.

What exactly can change

A review doesn’t always change the diagnosis of “cancer” itself. More often it clarifies details that treatment depends on:

  • tumor type — for example, ductal or lobular cancer, adenocarcinoma or a neuroendocrine tumor, sarcoma or another soft tissue tumor;
  • grade — this decides whether chemotherapy is needed;
  • invasive cancer or cancer in situ — these are different stages and different treatment;
  • receptors and HER2 — these determine hormone therapy and anti-HER2 drugs;
  • resection margins and lymph nodes — these decide whether a repeat operation or radiotherapy is needed;
  • whether there is enough tissue — sometimes a review shows that a new biopsy is needed for a precise answer.

Review or repeat biopsy

These are different things. A review is a new assessment of the same tissue. A repeat biopsy is a new piece of tissue. A repeat biopsy is needed when:

  • there is too little tissue for IHC and molecular tests;
  • the tumor has changed behavior — for example, it is growing on a treatment that used to work;
  • new lesions have appeared and it needs to be established whether it is the same tumor.

At progression the tumor’s biomarkers can change, so the doctor sometimes suggests a biopsy of a metastasis even when the original pathology isn’t in doubt.

When a review matters most

I recommend a review when:

  • the tumor is rare — sarcomas, neuroendocrine tumors, lymphomas, rare forms of breast cancer;
  • the report is uncertain — “cannot be excluded”, “more likely”, “IHC recommended”;
  • the result doesn’t fit the clinical picture — for example, the tumor behaves more aggressively than it “should” according to the report;
  • treatment depends on the details — borderline HER2, Ki-67 at a cut-off, doubts about the tumor type;
  • the tissue was examined at a small laboratory without experience in this tumor type;
  • expensive or demanding treatment is planned, and an error in the diagnosis would be costly.

How to get a review

  1. Obtain the slides and blocks from the laboratory or clinic where the test was done. They are usually released on written request. Check whether you need the material back — the blocks may be needed for future tests.
  2. Choose a laboratory. Ideally a cancer center’s reference laboratory that sees many cases of your tumor type.
  3. Send the material with supporting documents: a copy of the report, a summary with the clinical diagnosis, and the question to be answered (“clarify tumor type”, “assess HER2”).
  4. Store the originals properly. Blocks and slides don’t like heat and moisture; transport them in the laboratory’s packaging.

If you’re preparing for a consultation, the review can be started in parallel — the result may be ready by the time you meet. The list of documents is in the article “Preparing for an oncology consultation”.

How long a review takes

It depends on the laboratory and on whether additional tests are needed. A simple slide review takes less time than a review with new immunohistochemistry or molecular tests. Check the turnaround time with the laboratory in advance and weigh it against the treatment plan.

What speeds up a review:

  • a complete set: slides, blocks, a copy of the report, a summary;
  • a clearly worded question from your treating doctor;
  • ordering any additional tests needed to choose treatment at the same time — for example, HER2, MSI or a mutation panel.

Review and molecular tests in one go

If you are sending the blocks to a reference laboratory anyway, it makes sense to discuss with your oncologist right away which molecular tests will be needed for treatment. Then the material doesn’t have to be sent twice, and the results arrive together. Which tests exist is covered in the article “Targeted therapy and molecular tests”.

What to do if the results differ

A discrepancy is a reason to talk to your oncologist — not to panic, and not to pick the “nicer” version. Usually what helps is:

  • an additional test — repeat IHC, a molecular test from the block;
  • discussion at a tumor board with a pathologist present;
  • a third opinion at another reference laboratory, if the discrepancy is fundamental.

Questions to ask your doctor

  • Do I need a review, and what could it change?
  • Where is it best to have a review for my type of tumor?
  • Is there enough tissue in the blocks for additional tests?
  • Can we start treatment before the result is back?

If you have doubts about your report, I can help you decide whether a review is needed and what question to put to the pathologist — more about second opinions.

Sources

  1. Second-opinion pathologic review is a patient safety mechanism that helps reduce error and decrease waste — Journal of Oncology Practice (MD Anderson Cancer Center), 2014
  2. Breast pathology second review identifies clinically significant discrepancies in over 10% of patients — Journal of Surgical Oncology (MD Anderson Cancer Center), 2015
  3. The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors — PLoS One (French Sarcoma Group), 2018
  4. Second Opinions for Cancer Treatment — American Cancer Society, 2025

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.